Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deflazacort
Drug ID BADD_D02492
Description Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7.[A179449] Deflazacort delays the onset of muscle related complications resulting from DMD[A179455], prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340]
Indications and Usage is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Marketing Status Not Available
ATC Code H02AB13
DrugBank ID DB11921
KEGG ID D03671
MeSH ID C021988
PubChem ID 189821
TTD Drug ID D09WYX
NDC Product Code 57582-040; 64918-1111; 52856-503; 52856-501; 52856-504; 24002-0036; 52856-505; 52128-135; 22552-0027; 64918-1901; 52856-502
Synonyms deflazacort | Dezacor | Emflaza | Calcort | Zamene
Chemical Information
Molecular Formula C25H31NO6
CAS Registry Number 14484-47-0
SMILES CC1=NC2(C(O1)CC3C2(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)C(=O)COC(=O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin papilloma23.10.01.002; 16.26.01.002; 11.05.07.0010.000166%
Skin striae23.01.05.0020.000579%Not Available
Sleep apnoea syndrome22.02.01.013; 19.02.05.002; 17.15.05.0010.000248%
Speech disorder19.19.02.002; 17.02.08.003; 22.02.05.0340.000414%Not Available
Spinal compression fracture15.08.05.004; 14.04.04.003; 12.04.04.0010.000414%Not Available
Spinal fracture15.08.05.001; 12.04.04.0020.000331%
Strabismus06.05.02.004; 17.17.01.0090.000166%Not Available
Stress19.06.02.004--Not Available
Suicidal ideation19.12.01.003--
Swelling08.01.03.0150.000662%Not Available
Swelling face23.04.01.018; 10.01.05.0180.004139%Not Available
Tachycardia02.03.02.007--Not Available
Tearfulness19.15.02.0050.000166%Not Available
Thirst14.03.02.007; 08.01.09.0210.000248%Not Available
Toxic epidermal necrolysis12.03.01.015; 23.03.01.008; 11.07.01.006; 10.01.01.0060.000166%
Upper respiratory tract infection22.07.03.011; 11.01.13.0090.000579%
Urinary incontinence20.02.02.010; 17.05.01.0080.000248%
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.003--
Viral infection11.05.04.0010.001407%Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.008--Not Available
Vitamin D deficiency14.12.03.0030.000166%Not Available
Vomiting07.01.07.0030.005960%
Weight decreased13.15.01.0050.004884%
Weight increased13.15.01.0060.023593%
Wheezing22.03.01.0090.000248%
White blood cell count increased13.01.06.013--Not Available
Mobility decreased17.02.05.018; 15.03.01.003; 08.01.03.0300.001324%Not Available
The 7th Page    First    Pre   7 8 9    Next   Last    Total 9 Pages